Among the tumors injected with IFNβ-LNPs, TAMs displayed lower levels of the immunosuppressive M2 macrophage marker, CD206, along with increases in the anti-tumor M1 macrophage markers, CD80 and CD86 (Figure 5). The gene discussed is CD86; the disease is neoplasm.